Member Info for Bazzaman

Bless them, they do try though!

https://www.fool.co.uk/investing/2015/11/10/should-you-buy-prudential-plc-itv-plc-and-trifast-plc-following-tuesdays-updates/

Results due on 17th GLA.

http://www.investorschronicle.co.uk/2015/11/09/comment/simon-thompson/tapping-into-hidden-value-AzBTHDtTFNPubPWyY3bICP/article.html

QP shares have been falling a bit and decided to just about hold on because fundamentals look good - it's not very liquid and that can mean wide swings. Interesting statement today regarding a medical device launch, that's helping the price to swing up.

Half-year results out on Tuesday, looking for a SP climb on the back of them. GLA

Nice finish, GLA.

Maybe...........maybe not - flatters to deceive. GLA

finish today.......maybe..........

climbing well since the results

http://www.investorschronicle.co.uk/2015/11/04/tips-and-ideas/share-tips/inland-doubles-sales-7ATWjJgf7mhOoAo3EEjDTN/article.html

Jonas Crosland is doing an update on INL this afternoon, with Simon aiming to complete his early next week. GLA

In the results the PBT was £34.0m which included a £14.5m revaluation surplus which if deducted leaves £19.5m against a broker estimate of £15m. The last time INL reported the SP did not rise until Simon at IC explained his interpretation of the results. So far, neither IC or Shares mag have commented & Simon did not do his regular Monday update yesterday so am expecting him to provide an update today. I haven't seen anything in these results that are a cause for alarm. The NAV is 43.9 & typically in the past INL trades at close to double the NAV. which would put it at mid to late 80s. As always seems the case with INL patience seems to be well rewarded which sometimes challenges retail investors. Most institutional investors have run scared on investing in any AIM stocks due to the persistent fraud & under performance that occurs. Still think we are in for some interesting timnes. BOL all.

(QP.) is a niche pharmaceuticals supplier, but it also has a medical adherence division, which provides Biodose services and products that help patients to keep up with their medication regimes. In September, Biodose won a tender for an 18-month homecare contract with Yorkshire and Humber NHS Pharmaceutical Purchasing At the moment this is a low-tech business, which is making a small loss and accounted for 15% of revenues at the interim stage, but Quantum is launching Biodose Connect, which provides further growth prospects. Telemedicine product Biodose Connect provides live, remote monitoring and management of patients taking their medication. If medication is not taken or more than the prescribed amount is taken then a carer, nurse or pharmacist is alerted. This can help to stop unnecessary hospital admissions or home care. The niche pharma operations are the core of Quantum and this is where the major growth will come. Medical adherence provides potential for growth and the division should breakeven next year.

http://www.sharesmagazine.co.uk/articles/quick-fix-at-amino

Sometimes you have to pay a premium for quality. BOL.

http://www.investorschronicle.co.uk/2015/10/29/tips-and-ideas/share-tips/connect-to-amino-s-growth-cePXqRibnY8lJaM8wi3uTK/article.html

This site is playing up, kept getting error

I'm not convinced the sells that are showing are genuine, I think the 100,000 sell at 12.50 was Wallace's buy but I might be wrong.

This was posted on the ADVFN share chat - The EPRA NAV measure will certainly help in March as clarified today... Net assets attributable to shareholders were £88.8m at 30 June 2015 equating to 43.92p (2014 restated: 29.63p) per share. The major part of the Group's land bank is held as inventories at the lower of cost and net realisable value and it should be noted that the unrealised value within the portfolio of sites is significantly higher than the stated value. NAV is a key performance measure used in the real estate industry. However, IFRS NAV does not provide shareholders with the most relevant information on the fair value of the assets within an ongoing real estate company with a long term strategy. Accordingly, after consultation with our advisers, we have decided to adopt the accounting practices of the European Public Real Estate Association ("EPRA") to address this issue. Specifically, the EPRA NAV measure highlights the fair value of net assets on a long term, ongoing basis. While not recognising unrealised gains due to planning gains in the income statement, the adjusted value of trading assets and land subject to planning gains would reflect their current fair value under EPRA's NAV measure. We intend to introduce this additional disclosure when we report the Group's half year results for the 6 month period ending 31 December 2015 expected in March 2016.